glp 1 cardiovascular effects Effect of GLP-1 on Risk Factors Emulated Effects of Glucagon-Like Peptide

Low stamina, weight management difficulty, poor fat oxidation, improving endurance What if your medical team actually helped you live a longer, healthier life

Liao, C

And then you add use of Ozempic on top of it

The Clinical Data: Everything Published So Far Phase 1 First-in-Human (Oral Formulation) Published: The Lancet, June 2025 Participants: 144 adults with overweight or obesity (BMI 25.039.9), no diabetes Duration: Up to 12 weeks Dosing: Once-daily oral amycretin, up to 2 50 mg Results: - 50 mg dose: 10.4% mean body weight change - 2 50 mg dose: 13.1% mean body weight change - Placebo: 1.2% 13% weight loss in 12 weeks

Wu SY, Chiang YJ, Fisher SB, Sturgis EM, Zafereo ME , Nguyen S, Grubbs EG, Graham PH, Lee JE, Waguespack SG, Perrier ND